Skip to main content

. 1977 Feb;4(1):79–82. doi: 10.1111/j.1365-2125.1977.tb00672.x

Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.

J M Bell, C J Russell, J K Nelson, J G Kelly, D G McDevitt

PMCID: PMC1428989 PMID: 14661

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Bodem G., Chidsey C. A. Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther. 1973 Jan-Feb;14(1):26–29. doi: 10.1002/cpt197314126. [DOI] [PubMed] [Google Scholar]
Carruthers S. G., Kelly J. G., McDevitt D. G., Shanks R. G. Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther. 1974 May;15(5):497–509. doi: 10.1002/cpt1974155497. [DOI] [PubMed] [Google Scholar]
Coppen A., Turner P., Rowsell A. R., Padgham C. 5-Hydroxytryptamine (5-HT) in the whole-blood of patients with depressive illness. Postgrad Med J. 1976 Mar;52(605):156–158. doi: 10.1136/pgmj.52.605.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
Croxson M. S., Ibbertson H. K. Serum digoxin in patients with thyroid disease. Br Med J. 1975 Sep 6;3(5983):566–568. doi: 10.1136/bmj.3.5983.566. [DOI] [PMC free article] [PubMed] [Google Scholar]
Eichelbaum M., Bodem G., Gugler R., Schneider-Deters D., Dengler H. J. Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med. 1974 May 9;290(19):1040–1042. doi: 10.1056/NEJM197405092901902. [DOI] [PubMed] [Google Scholar]
Kampmann J., Skovsted L. The kinetics of propylthiouracil in hyperthyroidism. Acta Pharmacol Toxicol (Copenh) 1975 Sep;37(3):201–210. doi: 10.1111/j.1600-0773.1975.tb00836.x. [DOI] [PubMed] [Google Scholar]
Kampmann J., Skovsted L. The pharmacokinetics of propylthiouracil. Acta Pharmacol Toxicol (Copenh) 1974 Nov;35(5):361–369. doi: 10.1111/j.1600-0773.1974.tb00756.x. [DOI] [PubMed] [Google Scholar]
Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]
Shand D. G. Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs. 1974;7(1):39–47. doi: 10.2165/00003495-197407010-00003. [DOI] [PubMed] [Google Scholar]
Turner P. Beta-adrenergic receptor blocking drugs in hyperthyroidism. Drugs. 1974;7(1):48–54. doi: 10.2165/00003495-197407010-00004. [DOI] [PubMed] [Google Scholar]
Vesell E. S., Passananti G. T. Inhibition of drug metabolism in man. Drug Metab Dispos. 1973 Jan-Feb;1(1):402–410. [PubMed] [Google Scholar]
Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES